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Abstract. The aims of the present study were to identify the 
expression profile of microRNA (miR)‑143/145 in hepatitis B 
virus (HBV)‑associated hepatocellular carcinoma (HCC), 
explore its association with prognosis and investigate whether the 
serum miR‑143/145 expression levels may serve as a diagnostic 
indicator of HBV‑associated HCC. The microRNA (miRNA) 
chromatin immunoprecipitation dataset was obtained from 
The Cancer Genome Atlas (TCGA) and the Gene Expression 
Omnibus databases, and analyzed using the Wilcoxon 
signed‑rank test. It was observed that the expression of miR‑143 
and miR‑145 was decreased 1.5‑fold in HBV‑associated HCC 
samples compared with non‑tumor tissue in the TCGA and 
the GSE22058 datasets (P<0.01). Using the reverse transcrip-
tion‑quantitative polymerase chain reaction, it was further 
confirmed that miR‑143/145 and their host gene MIR143HG 
were downregulated in HBV‑associated HCC tissues compared 
with corresponding distal non‑tumor tissues. The lower level 
of miR‑143 and miR‑145 expression was associated with tumor 
differentiation, and may thus be responsible for a poor prognosis 
of patients with HBV‑associated HCC. The receiver‑operating 
characteristic (ROC) curves were used to explore the potential 
value of miR‑143 and miR‑145 as biomarkers for predicting 
HBV‑associated HCC tumorigenesis. In serum, miR‑143/145 
were identified to be significantly decreased in patients with 
HBV‑associated HCC compared with negative control patients, 
and their associated areas under the ROC curves were calculated 
at 0.813 and 0.852 (P<0.05), with each having a sensitivity 
and a specificity close to 0.80. These results indicated that the 
decreased expression of the miR‑143/145 cluster and their host 
gene MIR143HG in HBV‑associated HCC tissue was associated 
with prognosis, and each of these miRNAs may serve as a valu-
able diagnostic biomarker for predicting HBV‑associated HCC 
tumorigenesis.
Introduction
Hepatocellular carcinoma (HCC) is the third most common 
cause of cancer mortality worldwide. A variety of risk factors 
may promote HCC genesis, including hepatitis B virus (HBV) 
infection, hepatitis C virus infection, heavy alcohol consumption 
and non‑alcoholic fatty liver disease (1,2). In the last decade, a 
marked increase in the incidence of HBV‑associated HCC has 
been observed, particularly in China. Since the prognosis of 
patients with HCC is markedly dependent on the stage of the 
disease, strategies for early detection of HCC have been inves-
tigated.
MicroRNAs (miRNAs) are short 20‑22‑nucleotide single‑ 
stranded RNA molecules, which have been associated with 
epigenetic regulation in a range of diseases, including tumori-
genesis (3-5). miRNAs regulate gene expression by altering 
the stability or the translational efficiency of target mRNAs. 
A previous study demonstrated that miRNAs are detectable 
and stable in serum (6); therefore, research has focused on the 
possibility of using miRNAs as biomarkers for predicting the 
diagnosis and prognosis of several diseases.
Two human miRNAs, miRNA‑143 (miR‑143) and miR‑145 
have been investigated as biomarkers for several types of 
cancer. miR‑143 and miR‑145 are stably expressed homologous 
miRNAs located within the same host gene, MIR143HG (7). 
The first study to examine the miR‑143/145 cluster focused on 
HBV‑associated HCC. This study demonstrated that miR‑143 
expression was increased in HBV‑associated HCC tumors and 
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was associated with invasive and metastatic behavior of liver 
tumor cells (8). Conversely, evaluation of the miR‑143/145 cluster 
expression in other types of tumor, including colonic carcinoma, 
pulmonary carcinoma, esophageal carcinoma and prostatic 
carcinoma (9-12), demonstrated that the miR‑143/145 cluster 
expression level was decreased. This raises the question of why 
the miR‑143/145 cluster is overexpressed in HBV‑associated 
HCC‑derived tumors, but is underexpressed in other types of 
tumor. However, previous studies have produced contradictory 
results (13-15), demonstrating that the miR‑143/145 expression 
level was decreased in HBV‑associated HCC‑derived tumors 
which contradicts the results of another previously mentioned 
study (8). Furthermore, a previous study demonstrated that the 
expression of the miR‑143/145 cluster was negligible in liver 
tissues, including normal liver tissue or HBV‑associated HCC 
tissue (7). This controversy was investigated further in the 
present study.
In the present study, the expression profile of miR‑143 
and miR‑145 in HBV‑associated HCC tissues and non‑tumor 
tissues was investigated using chromatin immunoprecipitation 
(ChIP) data from The Cancer Genome Atlas (TCGA) and the 
Gene Expression Omnibus (GEO) datasets. Their expression 
in HBV‑associated HCC tissue was also validated using the 
reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR). The association between miR‑143/145 expres-
sion and specific clinical features including tumorigenesis, 
tumor progression and prognosis was subsequently examined. 
Finally, the serum expression of miR‑143 and miR‑145 was 
determined to evaluate their potential clinical applications. 
The receiver‑operating characteristic (ROC) curves were used 
to explore their potential value as biomarkers for predicting 
HBV‑associated HCC tumorigenesis.
Materials and methods
TCGA miRNA dataset. The miRNA expression profile of 
372 patients with HCC and 50 non‑tumor distal liver samples 
was obtained from the TCGA dataset (cancergenome.nih.gov). 
According to the clinical information, 102 patients with HBV 
infection were selected as negative control.
GEO dataset. The GEO database (16) was accessed to obtain 
the normalized miRNA microarray dataset GSE22058 (www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058), which 
represents the miRNA expression profile of tumor and adjacent 
non‑tumor tissues of 96 patients with HCC. From these patients, 
~88% were confirmed positive for the HBV antigen (17).
Identification of differentially expressed miRNAs. For each 
dataset, the Wilcoxon signed‑rank test was used to identify the 
differentially expressed genes between tumor and non‑tumor 
samples. The null hypothesis was that a gene was not differen-
tially expressed between the two groups and rejection of this 
hypothesis indicated that the gene was differentially expressed. 
A miRNA was considered upregulated if P<0.01 and its fold 
increase was ≥1.5. Downregulated miRNAs were similarly 
defined.
Clinical samples. HBV‑associated HCC tissues, matched distal 
non‑cancerous liver tissues and 5 ml venous peripheral blood 
were obtained from 85 patients with HBV‑associated HCC 
from February 2012 to January 2013 at the Provincial Hospital 
Affiliated to Shandong University (Jinan, China). The mean 
patient age was 53.2±9.3 years (range, 25‑75 years), and 70.6% 
of the patients were male. Ten tissue samples from patients with 
hepatic hemangioma and 5 ml venous peripheral blood from 
50 patients with chronic hepatitis B were collected as negative 
controls. All tissue samples were histologically confirmed by 
a pathologist using hematoxylin and eosin staining of cryosec-
tioned specimens. The criteria used for distal non‑cancerous 
liver tissues were absence of tumor cells and 5 cm distance 
from the tumors. Blood samples were collected in Vacutainer® 
serum separating tubes (BD Biosciences, Franklin Lakes, NJ, 
USA). Serum was collected by centrifugation at 2,000 x g 
for 10 min at 4˚C after allowing the blood to clot for 30 min. 
Written informed consent was obtained from each patient, and 
the consent procedure and study protocol were approved by 
the Medical Institutional Ethical Committee of the Provincial 
Hospital Affiliated to Shandong University.
Clinical features. Clinical features including histological 
grade, metastasis, cirrhosis, and complete tumor capsule were 
reported by pathologists following post‑surgical pathological 
examination of HBV‑associated HCC samples.
miRNA/mRNA extraction and RT‑qPCR. The mRNAiso Plus 
and microRNAiso Plus kits (Takara Biotechnology Co., Ltd., 
Dalian, China) were used for mRNA and miRNA extrac-
tion from liver tissue, respectively. The MiRCURY RNA kit 
(Exiqon A/S, Vedbaek, Denmark), a specific kit for extracting 
microRNA from the serum, was used to extract miRNA from 
serum samples in order to guarantee the validation of the 
concentration of microRNAs. The PrimeScript™ RT Reagent 
kit and SYBR Premix Ex Taq (Takara Biotechnology Co., 
Ltd.) were used for first‑strand cDNA synthesis and RT‑qPCR, 
respectively, according to the manufacturer's protocols. 
β‑actin was used for mRNA normalization. β‑actin forward, 
3'‑GGC ACC ACA CCT TCT ACA ATG‑5' and reverse, 3'‑TAG 
CAC AGC CTG GAT AGC AAC‑5'. RT‑qPCR for microRNAs 
was performed on a 480 PCR system (Roche Diagnostics, 
Basel, Switzerland), at 95˚C for 1 min followed by 45 cycles 
of 95˚C for 5 sec, 65˚C for 30 sec and 72˚C for 30 sec. The 
expression of miRNAs in serum samples was calculated using 
the comparison 2-∆∆Cq method (18) relative to RNU6B (U6). 
The following specific forward and reverse primers were used 
in pairs when amplifying miRNA: miR‑143 forward, 3'‑GTG 
CAG TGC TGC ATC TCT GGT‑5'; 143HG forward, 3'‑GTG 
AAG GCA GAG GAC ACA CCT‑5' and reverse, 3'‑AAA ACC 
GTG CAT TTG GCT G‑5'. The forward primers for miR‑145 
and U6 and the reverse primers for all microRNAs were 
purchased as finished products from Takara Biotechnology 
Co., Ltd. (cat. nos. SJD14025 and SJD14078). PCR product 
sizes were validated by electrophoresis using 2% agarose and 
12% polyacrylamide, 8 M urea gel (19). All kits were used 
according to the manufacturer's protocol. All the experiments 
were performed >3 times generating similar results and error 
bars represent the standard error of the mean of 6 repeats.
Statistical analysis. SPSS software (version 16.0; SPSS, Inc., 
Chicago, IL, USA) was used to analyze the data. Comparisons 
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between matched HBV‑associated HCC tissue and non‑tumor 
tissue was performed by paired Student's t‑test and Wilcoxon 
signed‑rank test. Unmatched continuous data were compared 
using an independent two‑tailed t‑test. The association 
between the expression of miR‑143, miR‑145 and MIR143HG 
is analyzed by Pearson correlation in HBV‑associated HCC 
tissues. The diagnostic value of serum miR‑143/145 expression 
was assessed by the area under the ROC curves (AUC). The 
diagnostic accuracy was assessed by sensitivity, specificity, 
positive predictive value and negative predictive value. P<0.05 
was considered to indicate a statistically significant difference.
Results
miRNA expression prof ile analysis in patients with 
HBV‑associated HCC reveals that miR‑143 and miR‑145 
are among the 63 differentially expressed miRNAs. The 
HBV‑associated HCC and non‑tumor tissue miRNA ChIP data 
were obtained from the TCGA and the GEO datasets (16,17). 
It was identified that in the HBV‑associated HCC samples, 
24 miRNAs were increased >1.5‑fold (P<0.01) and 39 miRNAs 
were decreased >1.5‑fold compared with the matched adjacent 
non‑tumor samples. miR‑143 and miR‑145 were among the 
39 significantly decreased miRNAs in the HBV‑associated 
HCC samples (Fig. 1). The expression of miR‑145 was signifi-
cantly downregulated in the HBV‑associated HCC samples 
compared with the non‑tumor samples from the GSE22058 
(P<0.001) and the TCGA datasets (P<0.001). Furthermore, the 
expression of miR‑143 was significantly downregulated in the 
HBV‑associated HCC samples compared with the non‑tumor 
samples from the GSE22058 (P<0.001) and the TCGA datasets 
(P=0.004).
miR‑143 and miR‑145 are downregulated in HBV‑associated 
HCC samples and their expression pattern is consistent 
with the expression pattern of the host gene, MIR143HG. To 
validate the expression profiles of miR‑143 and miR‑145 and 
investigate the association with their host gene MIR143HG 
(Fig. 2A), the expression of the miRNAs and the host gene 
MIR143HG long non‑coding RNA (lncRNA) were examined 
using RT‑qPCR in HCC and normal tissues. As presented 
in Fig. 2B, miR‑143 expression was significantly decreased 
in HCC tissue compared with matched distal non‑cancerous 
liver tissue (NT) (HCC=0.075 vs. NT=0.205; P<0.05, Student's 
t‑test). Furthermore, miR‑145 expression was significantly 
decreased in HCC tissue when compared with NT (HCC=0.055 
vs. NT=0.232; P<0.01, Student's t‑test). No significant differ-
ences in miR‑143 and miR‑145 expression were identified 
between NT and negative control samples (NC). These results 
suggest that decreased miR‑143 and miR‑145 expression may 
be an indicator of HBV‑associated HCC tumorigenesis.
To investigate the association between miR‑143, miR‑145 
and their host gene MIR143HG, MIR143HG expression was 
quantitatively assessed. As presented in Fig. 2B, MIR143HG 
expression was decreased in HCC tissue compared with NT 
(HCC=0.43). Linear regression analysis indicated that the 
Figure 1. hsa‑143/145 expression analysis using miRNA ChIP data from the GEO and the TCGA databases. (A) The expression of miR‑145 was decreased 
in the HBV‑associated HCC samples (n=96, 88% positive for HBV antigen) compared with the matched adjacent non‑tumor tissues (n=96) in the GSE22058 
database (**P<0.001, Wilcoxon signed‑rank test). (B) The expression of miR‑145 was significantly decreased in the HBV‑associated HCC samples (n=372) 
compared with the non‑tumor liver samples (n=50) in the TCGA dataset (**P<0.001; Wilcoxon signed‑rank test). (C) The expression of miR‑143 was decreased 
in the HBV‑associated HCC samples (n=96, 88% positive for HBV antigen) compared with the matched adjacent non‑tumor tissues (n=96) in the GSE22058 
database (**P<0.001, Wilcoxon signed‑rank test). (D) The expression of miR‑143 was decreased in the HBV‑associated HCC samples (n=102) compared with 
the non‑tumor liver samples (n=50) in the TCGA dataset (P=0.004, Wilcoxon signed‑rank test). *P<0.01. hsa, Homo sapiens; miRNA/miR, microRNA; GEO, 
Gene Expression Omnibus; TCGA, The Cancer Genome Atlas; ChIP, chromatin immunoprecipitation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
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expression patterns of miR‑143 and miR‑145 were consistent 
with that of their host gene, MIR143HG (Fig. 2C) (miR‑145 vs. 
miR‑143; P<0.001, miR‑143 vs. MIR143HG; P=0.001, miR‑145 
vs. MIR143HG; P=0.009).
miR‑143 and miR‑145 expression is associated with the histo‑
logical differentiation of HBV‑associated HCC tumors. To 
investigate the role of miR‑143/145 in HBV‑associated HCC, 
the expression level of the miRNAs was associated with key 
clinical features including tumor progression and disease 
prognosis. miR‑143/145 expression was not associated with 
the histological grade of the HBV‑associated HCC samples. 
However, as presented in Fig. 3A, the moderately differenti-
ated group had significantly increased miR‑143 expression 
compared with the well‑differentiated group (P=0.026). 
Similarly, miR‑145 expression in the moderately differentiated 
group was increased compared with the well‑differentiated 
group (P=0.012). miR‑143 and miR‑145 were significantly 
overexpressed in the well‑differentiated group compared with 
the negative control (P=0.004 and P=0.016, respectively). 
The expression of the miRNAs was also associated with the 
presence of metastasis, cirrhosis and complete tumor capsule 
(Fig. 3B‑D); however, no statistically significant association 
was detected. Similarly, no statistically significant association 
was identified with age or sex (data not shown). These results 
demonstrate that decreased miR‑143 and miR‑145 expression 
is associated with tumor differentiation and may be a useful 
indicator of poor prognosis for patients with HBV‑associated 
HCC.
Serum levels of miR‑143 and miR‑145 are decreased in patients 
with HBV‑associated HCC and may serve as a potential 
diagnostic biomarker for HBV‑associated HCC. The results 
of the present study confirmed that miR‑143 and miR‑145 were 
decreased in HBV‑associated HCC tissue. To evaluate their use 
in clinical applications, their expression was quantified in serum 
prior to and following surgical tumor excision. As presented 
in Fig. 4A, miR‑143 expression was identified to be signifi-
cantly decreased in the serum of patients with HBV‑associated 
HCC compared with NC (HCC=0.06 vs. NC=0.22; P<0.01, 
independent Student's t‑test). The miR‑145 expression was also 
identified to be significantly decreased in the serum of patients 
with HBV‑associated HCC compared with NC (HCC=0.13 vs. 
NC 0.27; P<0.01; Fig 4B).
Subsequently, the serum miR‑143 and miR‑145 RT‑qPCR 
data were used to generate ROC curves for each miRNA 
and determine the respective AUC. As presented in Fig. 4C 
and D, the AUC of the miR‑143 ROC curve was 0.813±0.04 
(mean ± standard error of the mean; 95% confidence interval, 
0.735‑0.892; P<0.01) and that of the miR‑145 ROC curve was 
0.852±0.039 (mean ± standard error of the mean; 95% confi-
dence interval, 0.776‑0.928; P<0.05).
Figure 2. Expression patterns of MIR143HG, miR‑143 and miR‑145 in HBV‑associated HCC tissue. (A) The genomic location of MIR143HG, which encodes 
miR‑143 and miR‑145 (7). (B) The expression patterns of MIR143HG, miR‑143 and miR‑145 in HBV‑associated HCC tissue (n=85), NT (n=85) and NC (n=10). 
Expression levels were determined using RT‑qPCR. U6 snRNA was used for miRNA normalization. Results are presented as the mean ± standard error of 
the mean. *P<0.05, **P<0.01, Student's t‑test. (C) Pearson correlation between miR‑143, miR‑145 and MIR143HG expression in HBV‑associated HCC tissue. 
**P<0.01. miRNA/miR, microRNA; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; NT, non‑cancerous liver tissue; NC, negative control; RT‑qPCR, 
reverse transcription‑quantitative polymerase chain reaction.
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Figure 3. Association of the miRNA expression patterns with several clinical features. (A) Tumors were characterized by pathological analysis as well, 
moderately or poorly differentiated. The expression of miR‑143 and miR‑145 was determined using RT‑qPCR. U6 snRNA was used for miRNA normaliza-
tion. Results are presented as the mean ± standard error of the mean. *P<0.05, **P<0.01, Student's t‑test. The HBV‑associated HCC samples were also grouped 
according to the following clinical features: (B) (+/‑) Metastasis, (C) (+/‑) cirrhosis or (D) (+/‑) complete tumor capsule. No statistically significant association 
was identified between these clinical features and the expression of miR‑143 and miR‑145. miRNA/miR, microRNA; HBV, hepatitis B virus; HCC, hepatocel-
lular carcinoma; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.
ZHAO et al:  miRNA‑143/145 IN HBV‑ASSOCIATED HCC6120
Figure 4. miR‑143 and miR‑145 serum levels are decreased in patients with HBV‑associated HCC and may be used to predict tumorigenesis. RT‑qPCR was 
used to determine the (A) miR‑143 and (B) miR‑145 expression levels in the serum samples. miR‑143 and miR‑145 expression was significantly decreased in 
the HBV‑associated HCC samples compared with NC. Results are presented as the mean ± standard error of the mean. **P<0.01, Student's t‑test. (C) The ROC 
curve of serum miR‑143 expression for predicting HBV‑associated HCC tumorigenesis. The AUC was calculated to be 0.813. (D) The ROC curve of serum 
miR‑145 expression for predicting HBV‑associated HCC tumorigenesis. The AUC was calculated to be 0.852. miRNA/miR, microRNA; HBV, hepatitis B 
virus; HCC, hepatocellular carcinoma; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction; ROC, receiver‑operating characteristic; AUC, 
area under the ROC curve.
Figure 5. Consolidated model for the role of miR‑143 and miR‑145 in HBV‑associated HCC. In this model, the expression of miR‑143, miR‑145 and their host 
gene MIR143HG is decreased in HBV‑associated HCC tissue, and their expression is associated with the histological grade of the tumor (*P<0.05). Serum 
miR‑143 and miR‑145 are decreased in patients with HBV‑associated HCC compared with NC, and may serve as potential diagnostic biomarkers to predict 
tumorigenesis in patients infected with HBV. miRNA/miR, microRNA; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ROC, receiver‑operating 
characteristic; AUC, area under the ROC curve; SE, standard error; CI, confidence interval.
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A threshold for each miRNA was selected to predict HCC 
between patients with HBV infection. The 1.194 miR‑145 
threshold identified 88.2% of patients with HBV‑associated 
HCC with a comparatively lower specificity of 78%. The 0.118 
miR‑143 threshold was characterized by 77.6% sensitivity and 
86% specificity (Fig. 5). The results of the present study indicate 
that the two miRNAs may potentially be used to predict HCC in 
patients infected with HBV, with a sensitivity and specificity of 
~0.80, according to the recommendations of the International 
Mesothelioma Interest Group for MPM biomarkers (20).
Discussion
According to GenBank, miR‑143 and miR‑145 are encoded 
by the MIR143HG gene, which is a non‑protein coding gene. 
miR‑143 and miR‑145 have distinct sequences, and are located 
in proximity within the MIR143HG gene. Previous studies have 
demonstrated decreased miR‑143/145 expression in colonic 
carcinoma, pulmonary carcinoma, esophageal carcinoma 
and prostatic carcinoma (9-12). However, their expression 
profile in HCC remains controversial. A previous study 
demonstrated increased expression (8), whereas decreased 
expression was demonstrated in others (14,15). By contrast, 
a previous study demonstrated that miR‑143/145 expression 
was markedly decreased in liver tissue (7). To investigate 
this further, miR‑143 and miR‑145 expression was examined 
in tissue and serum samples of patients with HBV‑associated 
HCC. In addition, serum miRNA data were used to evaluate 
the potential clinical application of miRNAs as biomarkers for 
HBV‑associated HCC.
In the present study, a model was developed to describe 
the role of the miR‑143/145 cluster in HBV‑associated HCC. 
As Fig. 5 indicates, the expression of miR‑143 and miR‑145 
was significantly decreased in tumor tissue of patients with 
HBV‑associated HCC compared with non‑tumor distal tissue. 
This was particularly evident in patients with moderately and 
poorly differentiated tumors. The miR‑143 and miR‑145 serum 
levels were also decreased in patients with HBV‑associated 
HCC in accordance with the expression profile observed in 
the tumor tissues. By contrast, the expression of MIR143HG 
in the serum presented no significant alteration in patients 
with HBV‑associated HCC compared with NC, even though 
MIR143HG was identified to be downregulated in tumor tissue. 
The ROC curves generated from miR‑143 and miR‑145 serum 
expression data indicated that serum miR‑143/145 expression 
may be a promising biomarker for predicting tumorigenesis in 
patients with HBV infection.
When examining the expression of a miRNA, its expres-
sion in tissue samples is first determined. However, when 
investigating its potential clinical application, examination 
of serum miRNA levels is required. HBV‑associated HCC 
is a serious condition, characterized by high morbidity and 
mortality, and early detection is crucial for effective surgical 
excision. Since the HCC biomarkers used currently, including 
serum α‑fetoprotein and the carcinoembryonic antigen, have 
limited sensitivity and specificity, novel biomarkers are 
required to improve the diagnosis and management of patients 
with liver diseases. It has been reported that tumor‑derived 
miRNAs are frequently released into the peripheral blood 
circulation and remain stable, protected from RNase (21). The 
results of the present study support this hypothesis. It was 
demonstrated that serum miR‑143/145 expression is consistent 
with the expression in tumor tissue and the expression levels 
of miR‑143/145 in patients with HBV‑associated HCC were 
decreased compared with NC. Taking into consideration the 
ROC curves as well, the results of the present study support the 
hypothesis that serum miR‑143/145 may be a potential diag-
nostic biomarker for HBV‑associated HCC. Further research 
is currently underway to validate this hypothesis and elucidate 
the underlying molecular mechanism of miR‑143/145‑mediated 
regulation of tumor biology.
Using miRNA ChIP and RT‑qPCR data, the results of the 
present study confirmed that miR‑143/145 and their host gene 
MIR143HG are downregulated in tumor tissue of patients 
with HBV‑associated HCC. It was also demonstrated that the 
expression of miR‑143/145 was associated with the histological 
differentiation of HBV‑associated HCC tissues. In addition, 
serum levels of miR‑143 and miR‑145 were examined and it 
was demonstrated that the two miRNAs were decreased in 
patients with HBV‑associated HCC compared with NC. On 
the basis of the ROC curves, the results of the present study 
suggest that serum miR‑143 or miR‑145 expression may be a 
valuable diagnostic biomarker for predicting tumorigenesis in 
patients with HBV‑associated HCC.
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